Why Is ARS PHARMACEUTICALS (SPRY) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 10 wire stories
ARS PHARMACEUTICALS (SPRY) is drawing unusual attention today. Our newswire has captured 10 stories on SPRY across 6 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for SPRY publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
AI sentiment, last 36h · averaged over 10 stories · 37/100 bearish
The headlines behind the move
Story flow · 9 stories on the wire, last 36h · hover or tap a dot for the headline
57m agoSeeking AlphaBEARISH 32Earnings
ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss
ARS Pharma (SPRY) plunges after-hours as it drops neffy direct-to-consumer marketing, targets top prescribers, cuts SG&A, and updates 2027 cash-flow...
1h agoSeeking AlphaBEARISH 38Earnings
ARS Pharmaceuticals GAAP EPS of -$0.63 misses by $0.14, revenue of $33.7M beats by $2.38M
ARS Pharmaceuticals (SPRY) Q2 earnings: GAAP EPS -$0.63 misses, revenue $33.7M up 114% beats estimates.
1h agoSEC 8-KNEUTRAL 50General
ARS Pharmaceuticals, Inc. (SPRY) files 8-K
Filed: 2026-08-13 AccNo: 0001193125-26-349127 Size: 857 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4h agoBusiness InsiderBEARISH 34General
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
San Diego, California--(Newsfile Corp. - August 13, 2026) - Robbins LLP reminds shareholders that a...
5h agoPR NewswireBEARISH 34General
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026
A securities class action alleges ARS Pharmaceuticals paired specific, confident statements about a July 1, 2026 CVS Caremark formulary date with only generalized risk language, leaving SPRY investors exposed to a 23.9% single-day decline. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- SueWallSt...
5h agoGlobeNewswireBEARISH 34General
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers. This lawsuit seeks to recover...
10h agoBusiness InsiderBEARISH 34General
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY)
Philadelphia, Pennsylvania--(Newsfile Corp. - August 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). What is The...
1d agoBusiness InsiderBEARISH 42General
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY
New York, New York--(Newsfile Corp. - August 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS...
1d agoBusiness InsiderBEARISH 34General
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) Who Suffered Losses to Contact the Firm Before October 5, 2026
New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox Kilsheimer LLP announces that a...
2d agoBarchartBEARISH 34General
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers. This lawsuit seeks to recover...
Frequently asked questions
Why is SPRY stock moving today?
ARS PHARMACEUTICALS (SPRY) is drawing unusual attention today. Our newswire has captured 10 stories on SPRY across 6 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100). The most recent driver: "ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss" (Seeking Alpha).
Is SPRY a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SPRY coverage reads 37/100 over 10 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →